BSR_04_0040_A3_S71
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- MYC_TARGETS_V2+0.410
- G2M_CHECKPOINT+0.390
- MYC_TARGETS_V1+0.370
- DNA_REPAIR+0.360
- OXIDATIVE_PHOSPHORYLATION+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.260
- SPERMATOGENESIS+0.230
- PROTEIN_SECRETION+0.210
- MTORC1_SIGNALING+0.200
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- ALLOGRAFT_REJECTION-0.570
- INFLAMMATORY_RESPONSE-0.570
- TNFA_SIGNALING_VIA_NFKB-0.520
- ANGIOGENESIS-0.480
- KRAS_SIGNALING_UP-0.460
- COMPLEMENT-0.430
- INTERFERON_GAMMA_RESPONSE-0.430
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20120289.LumB | — | B | 0.943 |
| 2 | BSR_15_0056_E1_S102 | — | B | 0.940 |
| 3 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.931 |
| 4 | AUR-AERX-TTM1-A-1-1-R-A742-41 | — | C | 0.924 |
| 5 | SRR35579806 | — | B | 0.923 |
| 6 | TCGA-AO-A0J3-01A-11R-A034-07 | — | B | 0.921 |
| 7 | SRR4195684 | — | — | 0.921 |
| 8 | SRR26320088 | — | — | 0.916 |
| 9 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.913 |
| 10 | BS_YETBN0RQ | medulloblastoma | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |